PMID- 11720639
OWN - NLM
STAT- MEDLINE
DCOM- 20011214
LR  - 20131121
IS  - 1521-737X (Print)
IS  - 1521-737X (Linking)
VI  - 1
IP  - 5
DP  - 1999 Nov-Dec
TI  - Dalteparin for acute coronary syndromes.
PG  - 329-36
AB  - Acute coronary syndromes account for tens of thousands of emergency room visits 
      and cost the United States healthcare system billions of dollars each year. 
      Dalteparin is a low molecular weight heparin (LMWH) recently approved for 
      treatment of unstable angina and non-Q wave myocardial infarction (NQWMI). The 
      LMWHs possess distinct advantages over unfractionated heparin (UFH). Some of 
      these advantages include administration by subcutaneous injection with no 
      intravenous access required; laboratory monitoring of activated partial 
      thromboplastin time (aPTT) is not required; improved side effect profile; and 
      more predictable and consistent anticoagulant response. In conjunction with 
      aspirin, dalteparin was evaluated for the treatment of unstable angina and NQWMI 
      in three large clinical trials. The FRISC study established the value of 
      short-term dalteparin in patients with unstable coronary artery disease, but 
      suggested that treatment with 120 IU/kg subcutaneously twice daily may be 
      required for more than 6 days. The FRIC trial determined there was no difference 
      between dalteparin and UFH in the acute setting for prevention of death or 
      myocardial infarction (MI). Similar to the FRISC trial, the FRIC trial failed to 
      demonstrate a benefit of dalteparin beyond the acute phase. The FRISC II study 
      demonstrated a significant decrease in the composite endpoint of death or MI in 
      the dalteparin group at 30 days, but not at 3 or 6 months. The early protective 
      effects of dalteparin could be used to lower the risk of events in patients 
      waiting for invasive procedures.
FAU - O'Loughlin, D C
AU  - O'Loughlin DC
AD  - Division of Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy and 
      Health Sciences, Long Island University, Brooklyn, New York 11201-5497, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Heart Dis
JT  - Heart disease (Hagerstown, Md.)
JID - 100887299
RN  - 0 (Anticoagulants)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Angina Pectoris/*drug therapy
MH  - Anticoagulants/*therapeutic use
MH  - Dalteparin/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Syndrome
EDAT- 2001/11/27 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/27 10:00
PHST- 2001/11/27 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/27 10:00 [entrez]
PST - ppublish
SO  - Heart Dis. 1999 Nov-Dec;1(5):329-36.